Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

CLDI

Calidi Biotherapeutics (CLDI)

Calidi Biotherapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:AMEX:CLDI
일자시간출처헤드라인심볼기업
2024/05/1505:05Business WireCalidi Biotherapeutics Reports First Quarter 2024 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
2024/05/0120:00Business WireCalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingAMEX:CLDICalidi Biotherapeutics Inc
2024/04/2320:00Business WireJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24AMEX:CLDICalidi Biotherapeutics Inc
2024/04/2005:05Business WireCalidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public OfferingAMEX:CLDICalidi Biotherapeutics Inc
2024/04/1621:31Business WireCalidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public OfferingAMEX:CLDICalidi Biotherapeutics Inc
2024/04/0920:00Business WireCalidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024AMEX:CLDICalidi Biotherapeutics Inc
2024/03/1605:05Business WireCalidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
2024/03/1120:00Business WireCalidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian CancerAMEX:CLDICalidi Biotherapeutics Inc
2024/02/1221:00Business WireCalidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming ConferenceAMEX:CLDICalidi Biotherapeutics Inc
2024/01/0821:00Business WireCalidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory BoardAMEX:CLDICalidi Biotherapeutics Inc
2023/12/1321:00Business WireCalidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy SummitAMEX:CLDICalidi Biotherapeutics Inc
2023/12/1221:00Business WireCalidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of DirectorsAMEX:CLDICalidi Biotherapeutics Inc
2023/11/2021:00Business WireCalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical MilestonesAMEX:CLDICalidi Biotherapeutics Inc
2023/11/1506:05Business WireCalidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial ResultsAMEX:CLDICalidi Biotherapeutics Inc
2023/11/0320:00Business WireCalidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)AMEX:CLDICalidi Biotherapeutics Inc
2023/11/0120:00Business WireCalidi Biotherapeutics Announces Key Leadership Promotions and New Board AppointmentAMEX:CLDICalidi Biotherapeutics Inc
2023/10/3020:00Business WireCalidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial OfficerAMEX:CLDICalidi Biotherapeutics Inc
2023/10/1020:00Business WireCalidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023AMEX:CLDICalidi Biotherapeutics Inc
2023/09/1318:50Business WireCalidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted ImmunotherapiesAMEX:CLDICalidi Biotherapeutics Inc
 검색 관련기사 보기:AMEX:CLDI